Thelial Technologies

Thelial Technologies is a biotechnology startup founded in 2009, with a focus on discovering and developing targeted carcinoma therapies through innovative drug discovery and repositioning for advancing novel cancer treatments. Their slogan, "Discovering and developing targeted carcinoma therapies through innovative drug discovery and repositioning for advancing novel cancer treatments," encapsulates their mission. The company's proprietary platform, theLiTE™ (Thelial – Live Targeted Epithelia), has proven to be a significant breakthrough in targeted carcinoma drug discovery. With a library of over 1200 drug candidates, they have identified six promising carcinoma-targeted drug candidates, thus validating theLiTE™. Additionally, they employ a strategic drug repositioning approach to identify new applications for existing drug compounds, showcasing their multifaceted approach to innovation. Furthermore, Thelial Technologies is simultaneously working on developing a novel treatment class that targets actin in cancer, showcasing their commitment to exploring various avenues for advancing cancer therapies. Their most recent funding of €50.00K came in the form of a grant investment by EASME - EU Executive Agency for SMEs in 01 December 2016. Thelial Technologies's dedication to pioneering approaches in cancer treatment makes it a compelling prospect for potential investors in the biotechnology and healthcare industries.